PRIMENENIE BISFOSFONATOV DLYa PROFILAKTIKI RAZVITIYa KOSTNYKh METASTAZOV U BOL'NYKh RAKOM MOLOChNOY ZhELEZY
- Authors: Semenov N.N1
-
Affiliations:
- Issue: No 8 (2013)
- Pages: 59-61
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281193
- ID: 281193
Cite item
Open Access
Access granted
Abstract
The article considers the results of controlled clinical studies on the use of bisphosphonates (primarily zoledronate) for the prevention of bone metastases in breast cancer. In general, the use of bisphosphonates significantly reduced the incidence of bone metastases, and the most pronounced effect was observed in menopausal women. In addition, bisphosphonates have increased disease-free survival and overall survival in this group of patients.
Keywords
Full Text
References
- Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationship for inhibition of pharnesyl dyphosphonate syntase in vitro and inhibition of bone resorbtion in vivo by nitrogene containing bisphosphonates. J Pharmacol Exp Ther 2001;296(2):235-42.
- Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral dodronate improves the overall survival of primary breast cancer patients with micro-metastases to the bone marrow - a long-term follow-up. Ann Oncol 2008;19(12):2007-11.
- Powles T.J., et al. Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer Clin Cancer Res 2006;12(20 Suppl):6301s.
- Saarto T., Vehmanen L., Blomqvist C., Elomaa I. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in nodepositive breast cancer patients. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22:527.
- Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancer. In 34th Annual San Antonio Breast 2005;146:1727-36.
- Diel I.J., Solomayer E.F., Seibel M.J., et al. Serum Bone Sialoprotein in Patients with Primary Breast Cancer Is a Prognostic Marker for Subsequent Bone Metastasis. Clin Cancer Res 1999;5:3914.
- Henry D.H., Costa L., Goldwasser F., et al. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. J Clin Oncol 2011; 29:1125-32.
- Fizazi K., Carducci M.A., Smith M.R., et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. ASCO Meeting Abstracts 2010;28:LBA4507.
- Stopeck A.T., Lipton A., Body J.J., et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol 2010;28: 5132-39.
- Kanis J.A., et al. Clodronate decrease the frequency of skeletal metastases in woman with beast cancer. Bone 1996;19(6):663-67.
- Coleman R., de Boer R., Eidtmann H., et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013;24(2): 398-405.
- Paterson A.H.G., Anderson S.J., Lembersky B.C., et al. NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy - Final Analysis. Cancer Res 2011;71:S2-3.
- Coleman R.E., Marshall H., Cameron D., et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
- Mbus V., Diel I.J., Harbeck N., et al. GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer - 1st Interim Efficacy Analysis. Cancer Res 2011; 71:S2-4.
- Schneider А., Kalikin L.M., Mattos A.C., et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology Cancer Symposium (Abstr S1-2); San Antonio, TX. 2011.
Supplementary files
